Table 2.
Nonhematological toxicities in patients included in phase 2
Adverse event | All grade (%) | Grade > 3, % |
---|---|---|
Diarrhea | 6.7 | 0 |
Fatigue | 16.9 | 0 |
Musculoskeletal | 33.3 | 0 |
Stomatitis | 70 | 3 |
Skin disorders | 36.7 | 0 |
Bleeding | 13.3 | 0 |
Hypertriglyceridemia | 70 | 0 |
Hypercholesterolemia | 23.3 | 0 |
AST increase | 7 | 3 |
ALT increase | 7 | 3 |
Bronchitis | 3 | 0 |
Pneumonitis | 7 | 7 |
Urinary tract infection | 7 | 3 |
Renal failure | 3 | 3 |
Others | 20 | 0 |
ALT indicates alanine aminotransferase; and AST, aspartate aminotransferase.